106 related articles for article (PubMed ID: 23906458)
21. Survival improvement of young patients, aged 16-23, with Hodgkin lymphoma (HL) during the last three decades.
Koumarianou AA; Xiros N; Papageorgiou E; Pectasides D; Economopoulos T
Anticancer Res; 2007; 27(2):1191-7. PubMed ID: 17465262
[TBL] [Abstract][Full Text] [Related]
22. Hodgkin's lymphoma in adolescents treated with adult protocols: a report from the German Hodgkin study group.
Eichenauer DA; Bredenfeld H; Haverkamp H; Müller H; Franklin J; Fuchs M; Borchmann P; Müller-Hermelink HK; Eich HT; Müller RP; Diehl V; Engert A
J Clin Oncol; 2009 Dec; 27(36):6079-85. PubMed ID: 19901121
[TBL] [Abstract][Full Text] [Related]
23. Clinical characteristics and prognostic factors of primary extranodal classical Hodgkin lymphoma: a retrospective study.
Yang M; Ping L; Liu W; Xie Y; Aliya ; Liu Y; Nuersulitan R; Zhu J; Wu M; Song Y
Hematology; 2019 Dec; 24(1):413-419. PubMed ID: 30922173
[TBL] [Abstract][Full Text] [Related]
24. The absolute lymphocyte to monocyte ratio is associated with poor prognosis in classical Hodgkin lymphoma patients younger than 60 years of age.
Koh YW; Jung SJ; Yoon DH; Suh C; Cha HJ; Go H; Kim JE; Kim CW; Huh J
Hematol Oncol; 2015 Sep; 33(3):133-40. PubMed ID: 25224646
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of Bcl-2, tumor-associated macrophages, and total neoplastic and inflammatory lymph node involvement in advanced stage classical Hodgkin's lymphoma.
Jakovic LR; Mihaljevic BS; Jovanovic MD; Bogdanovic AD; Andjelic BM; Bumbasirevic VZ
Onkologie; 2012; 35(12):733-9. PubMed ID: 23207618
[TBL] [Abstract][Full Text] [Related]
26. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group.
Engert A; Ballova V; Haverkamp H; Pfistner B; Josting A; Dühmke E; Müller-Hermelink K; Diehl V;
J Clin Oncol; 2005 Aug; 23(22):5052-60. PubMed ID: 15955904
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of T-cell or cytotoxic molecules phenotype in classical Hodgkin's lymphoma: a clinicopathologic study.
Asano N; Oshiro A; Matsuo K; Kagami Y; Ishida F; Suzuki R; Kinoshita T; Shimoyama Y; Tamaru J; Yoshino T; Kitamura K; Fukutani H; Morishima Y; Nakamura S
J Clin Oncol; 2006 Oct; 24(28):4626-33. PubMed ID: 16954517
[TBL] [Abstract][Full Text] [Related]
28. [Primary refractory and relapsed Hodgkin lymphoma with unfavorable prognosis].
Tarasenkova AA; Filatova LV; Gershanovich ML; Semiglazova TIu
Vopr Onkol; 2012; 58(1):101-9. PubMed ID: 22629838
[TBL] [Abstract][Full Text] [Related]
29. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials.
Böll B; Görgen H; Fuchs M; Pluetschow A; Eich HT; Bargetzi MJ; Weidmann E; Junghanß C; Greil R; Scherpe A; Schmalz O; Eichenauer DA; von Tresckow B; Rothe A; Diehl V; Engert A; Borchmann P
J Clin Oncol; 2013 Apr; 31(12):1522-9. PubMed ID: 23509310
[TBL] [Abstract][Full Text] [Related]
30. [HIV-related lymphoma in a public hospital in Chile. Analysis of 55 cases].
Cabrera ME; Silva G; Soto A; Roselló R; Castro C; Martínez V; Ballesteros J; Blamey R; Garreaud C
Rev Med Chil; 2012 Feb; 140(2):243-50. PubMed ID: 22739956
[TBL] [Abstract][Full Text] [Related]
31. Long-term outcome of treatment for Hodgkin's disease: the University Hospital Sofia experience.
Gocheva L; Koleva I
Klin Onkol; 2010; 23(1):34-42. PubMed ID: 20192072
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of the ratio of absolute neutrophil count to absolute lymphocyte count in classic Hodgkin lymphoma.
Koh YW; Kang HJ; Park C; Yoon DH; Kim S; Suh C; Kim JE; Kim CW; Huh J
Am J Clin Pathol; 2012 Dec; 138(6):846-54. PubMed ID: 23161719
[TBL] [Abstract][Full Text] [Related]
33. [A Real-World Single-Center Study of Adult Hodgkin's Lymphoma].
Wang LL; Tian L; Dong F; Yang P; Wan W; Li QH; Ma L; Gao JJ; Wang JJ; Zhao W; Jing HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):428-433. PubMed ID: 38660847
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of CD20 expression in classical Hodgkin lymphoma: a clinicopathological study of 119 cases.
Tzankov A; Krugmann J; Fend F; Fischhofer M; Greil R; Dirnhofer S
Clin Cancer Res; 2003 Apr; 9(4):1381-6. PubMed ID: 12684408
[TBL] [Abstract][Full Text] [Related]
35. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma.
Sieniawski M; Franklin J; Nogova L; Glossmann JP; Schober T; Nisters-Backes H; Diehl V; Josting A
J Clin Oncol; 2007 May; 25(15):2000-5. PubMed ID: 17420510
[TBL] [Abstract][Full Text] [Related]
36. Impact of the Epstein-Barr virus positivity on Hodgkin's lymphoma in a large cohort from a single institute in Korea.
Koh YW; Yoon DH; Suh C; Huh J
Ann Hematol; 2012 Sep; 91(9):1403-12. PubMed ID: 22526365
[TBL] [Abstract][Full Text] [Related]
37. Spleen involvement in Hodgkin's lymphoma: assessment and risk profile.
Rueffer U; Sieber M; Stemberg M; Gossmann A; Josting A; Koch T; Grotenhermen F; Diehl V;
Ann Hematol; 2003 Jul; 82(7):390-6. PubMed ID: 12764547
[TBL] [Abstract][Full Text] [Related]
38. Tumor associated macrophages in relapsed and refractory Hodgkin lymphoma.
Casulo C; Arcila M; Bohn OL; Teruya-Feldstein J; Maragulia J; Moskowitz CH
Leuk Res; 2013 Sep; 37(9):1178-83. PubMed ID: 23706570
[TBL] [Abstract][Full Text] [Related]
39. Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials.
Shimabukuro-Vornhagen A; Haverkamp H; Engert A; Balleisen L; Majunke P; Heil G; Eich HT; Stein H; Diehl V; Josting A
J Clin Oncol; 2005 Aug; 23(24):5739-45. PubMed ID: 16009944
[TBL] [Abstract][Full Text] [Related]
40. [Prognostic factors of primary non-Hodgkin's lymphoma of the nasal cavity--a report of 129 cases].
Yao B; Li YX; Fang H; Jin J; Liu XF; Yu ZH
Ai Zheng; 2006 Apr; 25(4):465-70. PubMed ID: 16613682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
